Clinical trial

Safety and Efficacy of Tegaserod in Opioid-induced Constipation in Patients With…

NCT00414024 · Novartis, Industry · Terminated

Key facts

NCT number NCT00414024
Title Safety and Efficacy of Tegaserod in Opioid-induced Constipation in Patients With Non-cancer Pain.
Official title An Open Label 52-week Study to Evaluate the Safety and Efficacy of Tegaserod Given Orally for the Treatment of Opioid-induced Constipation (OIC) in Patients With Chronic Non-cancer Pain
Lead sponsor Novartis, Industry
Status Terminated
Phase Phase 3
Study type Interventional
Conditions Opioid-induced Constipation
Intervention type Drug
Interventions Tegaserod
Enrollment 11
Start date Feb 1, 2007
Primary completion May 1, 2007
Completion May 1, 2007
First posted Dec 20, 2006
Last update posted Apr 20, 2012
Countries China, Egypt, Singapore, Taiwan, United States, Venezuela

At a glance

  • 1–9 Study sites
  • No Results posted
  • None Linked FDA submissions

Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.

About ClinicalTrials.gov studies

ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.

Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date:

Browse all ClinicalTrials.gov studies